| 1.51 0.01 (0.67%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.85 |
1-year : | 2.03 |
| Resists | First : | 1.59 |
Second : | 1.74 |
| Pivot price | 1.51  |
|||
| Supports | First : | 1.35 |
Second : | 1.12 |
| MAs | MA(5) : | 1.53 |
MA(20) : | 1.5 |
| MA(100) : | 1.59 |
MA(250) : | 2 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 60.1 |
D(3) : | 59.9 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 3.28 | Low : | 1.33 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COCP ] has closed above bottom band by 46.4%. Bollinger Bands are 8.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.57 - 1.58 | 1.58 - 1.59 |
| Low: | 1.49 - 1.5 | 1.5 - 1.51 |
| Close: | 1.49 - 1.51 | 1.51 - 1.52 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Mon, 01 Apr 2024
Do Traders Think Cocrystal Pharma Inc (COCP) Can Turn Around Monday? - InvestorsObserver
Tue, 19 Mar 2024
Cocrystal Pharma Advances Influenza A Treatment Development - TipRanks.com - TipRanks
Mon, 10 Apr 2023
Penny Stocks To Buy Now? 4 Under $3 To Watch This Week - Penny Stocks
Fri, 30 Jul 2021
Cocrystal Pharmaceuticals Inc. (NASDAQ: COCP) Says Its COVID-19 Proteases Inhibitor CDI-45205 Effective Against ... - BP Journal
Sun, 29 Nov 2020
Is Cocrystal Pharma, Inc. (COCP) A Good Stock To Buy? - Yahoo Finance
Tue, 03 Nov 2020
Cocrystal Pharma Inc (NASDAQ:COCP) Reveals Promising Toxicity Data From Its CC-42344 Lead Molecule Against ... - BP Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 30 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.7 % |
| Return on Equity (ttm) | -54.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.81 |
| PEG Ratio | 0 |
| Price to Book value | 0.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|